Showing results (81-90 of 109) with videos related to

Sort By:
Pageof 11
Breast (Edinburgh, Scotland)|July 17, 2023
Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B)Hiroko Masuda, Yuko Tanabe, Hitomi Sakai, et al.
Scientific Reports|March 22, 2025
Artificial intelligence system for predicting hand-foot skin reaction induced by vascular endothelial growth factor receptor inhibitorsTaro Yamanaka, Jumpei Ukita, Dongyi Xue, et al.
Cancer Medicine|March 14, 2023
Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355Masaya Hattori, Norikazu Masuda, Toshimi Takano, et al.
Cancer Science|March 8, 2017
Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancerShigehiro Koganemaru, Naoko Inoshita, Yuji Miura, et al.
BMC Cancer|April 17, 2020
Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patientsYuko Tanabe, Seiji Shiraishi, Kenji Hashimoto, et al.
BMC Cancer|October 24, 2019
Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic reviewMomoko Takahashi, Yukinori Ozaki, Rika Kizawa, et al.
BMC Cancer|October 18, 2019
Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancerTsutomu Iwasa, Junji Tsurutani, Satomi Watanabe, et al.
Eclinicalmedicine|August 7, 2024
Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trialMasato Takahashi, Yuichiro Kikawa, Kosuke Kashiwabara, et al.
Investigational New Drugs|March 27, 2015
Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumorsShinji Nakamichi, Hiroshi Nokihara, Noboru Yamamoto, et al.
Cancer Science|January 15, 2026
Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup AnalysisMasato Takahashi, Hirofumi Mukai, Toshimi Takano, et al.
Pageof 11